Skip to main content

Latest News

NICE approves use of new treatment for advanced metastatic bladder cancer

Enfortumab Vedotin combined with Pembrolizumab will now be available for eligible patients in the UK

The British Association of Urological Surgeons (BAUS) welcomes the decision by the National Institute for Health and Care Excellence (NICE) to approve the use of combination therapy enfortumab vedotin (Padcev) with pembrolizumab as a first-line treatment for untreated unresectable or metastatic urothelial (bladder) cancer in patients who are eligible for platinum-based chemotherapy. Urothelial cancer affects cells that form the inner...

Upcoming Event

8 – 12 Sep 2025

2025 World Congress of Endourology & Uro-Technology

Phoenix Convention Center, 100 N 3rd Street, Phoenix, AZ 85004, USA

Use the link below for further information about registration & abstract submission